This article was originally published in The Gray Sheet
NIRTOP randomized study of 305 patients at 15 international centers demonstrates a 6.3% restenosis rate for lesions greater than 3 mm treated with the NirFlex bare metal coronary stent. The treatment arm showed late-loss rate of 0.65 mm in addition to target vessel revascularization rates of 4.4%, 7% and 8.9% at 180 days, 210 days and 280 days, respectively. Antonio Colombo, MD, San Raffaele Hospital, Milan, Italy, served as the study's principal investigator...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.